Top Highlights in Hepatology: The Liver Meeting 2014
Factors associated with an increased risk for PSC recurrence include a high Model for End-Stage Liver Disease score, first-degree relative donors, post-transplant cytomegalovirus infection, and early biliary anastomotic complications. Gordon and ...
Medscape - Wed, 07 Jan 2015 07:57

New hope for PBC liver disease
Primary biliary cirrhosis, or PBC, is a slow acting liver disease that can lead to scarring and the need for a liver transplant. PBC affects 10 times as many women than men and is not related to drinking alcohol. While there is no cure, a promising new ...
ABC30.com - Sat, 17 Jan 2015 16:29



Intercept Receives Breakthrough Therapy Designation From FDA for Obeticholic ...
OCA is currently being developed for the treatment of several chronic liver diseases, including primary biliary cirrhosis (PBC), NASH and primary sclerosing cholangitis (PSC). "We are very pleased to have received breakthrough therapy designation for ...
GlobeNewswire (press release) - Thu, 29 Jan 2015 13:00

Intercept Pharmaceuticals -- Where Are The Mega Millions?
Forbes - Fri, 30 Jan 2015 11:30

Intercept Pharmaceuticals (ICPT) Receives Breakthrough Therapy Designation ...
InvestorGuide - Fri, 30 Jan 2015 06:26

Intercept Pharmaceuticals OCA Now Breakthrough Therapy
Zacks.com - Fri, 30 Jan 2015 12:48

Intercept Pharmaceuticals Shoots Up On Breakthrough Therapy Designation For ...
Bidness ETC - Fri, 30 Jan 2015 03:49



Treating liver disease
The treatment also depends on whether the patient has acute or chronic liver disease, whether one is dealing with fibrosis or cirrhosis, and whether the liver disease is the result of a viral infection, an autoimmune hepatitis, a genetically inherited ...
Health24 - Fri, 30 Jan 2015 04:56



Furry friends can enhance your health
In 2009, she was diagnosed with a chronic liver condition known as primary biliary cirrhosis or PBC, caused by an autoimmune disorder where the immune system attacks its own cells. The only cure is a liver transplant should one reach the point where ...
The Tennessean - Thu, 29 Jan 2015 10:56

FDA grants breakthrough therapy designation to obeticholic acid for NASH
It is currently being developed for nonalcoholic steatohepatitis (NASH), primary biliary cirrhosis and primary sclerosing cholangitis. “We are very pleased to have received breakthrough therapy designation for NASH with liver fibrosis, as it will ...
Healio - Fri, 30 Jan 2015 10:33

Biliary Cirrhosis Therapeutic Pipeline Review H2 2014 Report at ...
The report "Biliary Cirrhosis – Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Biliary Cirrhosis. Primary biliary cirrhosis is a long-term liver disease in which the bile ducts in the liver become damaged.
Press Release Rocket - Mon, 05 Jan 2015 11:34

Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog
The company stated that according to recent epidemiological studies, over 10% of the U.S. population suffers from NASH with more than 60% of the patients expected to have liver fibrosis or cirrhosis as a result of disease progression. Given that no ...
Nasdaq - Fri, 30 Jan 2015 12:48


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014